Angelman syndrome (AS) is a rare neurogenetic disorder that affects approximately one in 15,000 people – approximately 500,000 individuals worldwide. Children and adults with AS typically have balance issues, motor impairment and can have debilitating seizures. Some individuals never walk. Most do not speak. Disruptive sleep also can be a serious challenge to the individual and caretaker(s).
Individuals with AS require continuous care and are unable to live independently. They have a normal life expectancy. This is life today for people living with Angelman syndrome, but hope is here. Scientists believe that AS has the greatest potential for being cured when compared to any other neurogenetic disorder, and FAST has a plan well underway to achieve just that.